Alejandra Carvajal
CIK 1645755 · Chief Legal Officer · last filed 2026-08-05
Alejandra Carvajal is a Chief Legal Officer who has filed 39 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for CTMX, was dated Aug 5, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $251.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
840 MEMORIAL DRIVE, 5TH FLOOR
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTMX | Chief Legal Officer | 100,000 | $2.52 | $251.5K | $0 | 1 | 2026-08-05 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | SVP, Chief Legal Officer | 0 | $29.08 | $0 | -$79.2K | 12 | 2026-01-06 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Chief Legal Officer | 0 | — | — | -$1.39M | 20 | 2020-10-01 |
| Dare Bioscience, Inc. (CERU) Delisted | VP, General Counsel | — | — | — | $0 | 4 | 2017-01-09 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-05 | CTMX | Grant (A) | +100,000 | $0 | EDGAR |
| 2026-01-06 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | −3,131 | $0 | EDGAR |
| 2025-01-17 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +7,404 | -$3.0K | EDGAR |
| 2025-01-17 | Mersana Therapeutics, Inc. (MRSN) Delisted | Notice (144) | −5,096 | -$3.1K | EDGAR |
| 2025-01-16 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +1,548 | -$600 | EDGAR |
| 2025-01-15 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +5,628 | -$2.2K | EDGAR |
| 2024-10-07 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +36,313 | -$27.2K | EDGAR |
| 2024-10-07 | Mersana Therapeutics, Inc. (MRSN) Delisted | Notice (144) | −8,089 | -$16.3K | EDGAR |
| 2024-01-17 | Mersana Therapeutics, Inc. (MRSN) Delisted | Mixed | +7,077 | -$11.9K | EDGAR |
| 2023-09-07 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.